Investment analysts at Cann assumed coverage on shares of Agios Pharmaceuticals Inc. (NASDAQ:AGIO) in a report issued on Monday. The brokerage set a “market perform” rating on the biopharmaceutical company’s stock.

A number of other research analysts have also recently issued reports on AGIO. Goldman Sachs Group Inc. reissued a “neutral” rating and set a $46.00 price objective on shares of Agios Pharmaceuticals in a report on Wednesday, August 10th. BTIG Research initiated coverage on Agios Pharmaceuticals in a report on Friday, August 19th. They set a “neutral” rating for the company. Canaccord Genuity reissued a “buy” rating and set a $90.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, September 8th. Zacks Investment Research cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, October 5th. Finally, Needham & Company LLC initiated coverage on Agios Pharmaceuticals in a report on Monday, October 24th. They set a “buy” rating and a $60.00 price objective for the company. Six analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $61.94.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals (NASDAQ:AGIO) traded down 4.35% during trading on Monday, hitting $60.90. 379,545 shares of the stock traded hands. Agios Pharmaceuticals has a 52 week low of $33.50 and a 52 week high of $71.49. The firm’s 50-day moving average is $54.47 and its 200 day moving average is $48.35. The stock’s market cap is $2.56 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.52) by $0.11. The company had revenue of $8.98 million for the quarter, compared to the consensus estimate of $7.82 million. Agios Pharmaceuticals had a negative net margin of 341.56% and a negative return on equity of 53.39%. The firm’s revenue was up 63.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.07) earnings per share. Equities research analysts forecast that Agios Pharmaceuticals will post ($5.15) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another website, it was copied illegally and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2016/11/28/agios-pharmaceuticals-inc-agio-research-coverage-started-at-cann.html.

In other news, insider Scott Biller sold 5,000 shares of the business’s stock in a transaction dated Wednesday, October 5th. The stock was sold at an average price of $55.00, for a total transaction of $275,000.00. Following the completion of the transaction, the insider now directly owns 48,270 shares in the company, valued at approximately $2,654,850. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Lewis Clayton Jr. Cantley sold 627 shares of the business’s stock in a transaction dated Tuesday, September 27th. The stock was sold at an average price of $54.15, for a total value of $33,952.05. Following the transaction, the director now owns 109,659 shares of the company’s stock, valued at $5,938,034.85. The disclosure for this sale can be found here. 10.55% of the stock is owned by corporate insiders.

Several institutional investors have recently bought and sold shares of AGIO. Price T Rowe Associates Inc. MD raised its position in Agios Pharmaceuticals by 49.0% in the third quarter. Price T Rowe Associates Inc. MD now owns 1,239,924 shares of the biopharmaceutical company’s stock valued at $65,493,000 after buying an additional 407,975 shares during the last quarter. Credit Suisse AG raised its position in Agios Pharmaceuticals by 22.5% in the third quarter. Credit Suisse AG now owns 122,349 shares of the biopharmaceutical company’s stock valued at $6,462,000 after buying an additional 22,462 shares during the last quarter. Redmile Group LLC bought a new position in Agios Pharmaceuticals during the third quarter valued at about $38,976,000. Baker BROS. Advisors LP bought a new position in Agios Pharmaceuticals during the third quarter valued at about $10,982,000. Finally, Capital International Investors raised its position in Agios Pharmaceuticals by 0.3% in the third quarter. Capital International Investors now owns 1,504,896 shares of the biopharmaceutical company’s stock valued at $79,489,000 after buying an additional 3,859 shares during the last quarter. Institutional investors own 89.27% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. Its cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

5 Day Chart for NASDAQ:AGIO

Receive News & Stock Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.